Company intelligence / Profile preview

Metadeq Diagnostics

Delaware, United Statesmetadeq.com ↗

Ownership: Private
Development stage: Commercial

Overview

Metadeq’s HeparDx™ blood test demonstrated high sensitivity, specificity, and accuracy for diagnosing both MASH/NASH and liver fibrosis in peer-reviewed clinical studies. The technology outperformed other non-invasive tests in head-to-head comparisons. Data from a 250-patient prospective study undergoing liver biopsies was published in Gut journal. Further validation is ongoing.

Therapeutic areas: Metabolic DisordersGastroenterology
Modalities: Diagnostic test (blood-based)Liquid biopsy
Industry: Protein Biomarker Diagnostics

Drug pipeline

1 asset

HeparDx

Commercial

Indications: MASH, Liver fibrosis

Partnerships

No major pharmaceutical or biotech partnerships disclosed as of June 2025.

Beyond the preview

Go deeper on Metadeq Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Metadeq Diagnostics.

Explore the full profile